ConductScience.org, home

Paper40908522

Therapeutic Targets for Myocardial Fibrosis: A Comprehensive Review of Current and Emerging Approaches.

Wal A and 6 others. Cardiovasc Hematol Disord Drug Targets, 2026. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Therapeutic Targets for Myocardial Fibrosis: A Comprehensive Review of Current and Emerging Approaches. Papers, record 40908522. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40908522

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Therapeutic Targets for Myocardial Fibrosis: A Comprehensive Review of Current and Emerging Approaches.
PubMed
Journal
Cardiovasc Hematol Disord Drug Targets
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2026-07-21
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wal AAnkita
2Rawat AAnurag
3Verma RRakesh
4Rasheed AAzhar
5Panigrahy UPUttam Prasad
6Das AAnwesha
7Gasmi AAmin

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
MyocardiumMajor topic
CardiomyopathiesMajor topic
Cardiovascular DiseasesMajor topic
Humans
Fibrosis
Animals
Molecular Targeted Therapy

Source PubMed

Download CSV of topics

References202

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132317975Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety.Front Pharmacol2020https://conductscience.org/library/papers/32317975PubMed
233501848Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association.Circulation2021https://conductscience.org/library/papers/33501848PubMed
328157267Myocardial fibrosis: biomedical research from bench to bedside.Eur J Heart Fail2017https://conductscience.org/library/papers/28157267PubMed
432862327Myocardial Fibrosis in Heart Failure: Anti-Fibrotic Therapies and the Role of Cardiovascular Magnetic Resonance in Drug Trials.Cardiol Ther2020https://conductscience.org/library/papers/32862327PubMed
533014530Roles of Biomarkers in Myocardial Fibrosis.Aging Dis2020https://conductscience.org/library/papers/33014530PubMed
632955172Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?EMBO Mol Med2020https://conductscience.org/library/papers/32955172PubMed
728565750Myocardial fibrosis in congenital and pediatric heart disease.Exp Ther Med2017https://conductscience.org/library/papers/28565750PubMed
836247487Detection of myocardial fibrosis: Where we stand.Front Cardiovasc Med2022https://conductscience.org/library/papers/36247487PubMed
933135058Cardiac fibrosis.Cardiovasc Res2021https://conductscience.org/library/papers/33135058PubMed
1036675283Signaling Pathways and Potential Therapeutic Strategies in Cardiac Fibrosis.Int J Mol Sci2023https://conductscience.org/library/papers/36675283PubMed
1136979345Diffuse Myocardial Fibrosis on Cardiac Magnetic Resonance Imaging Is Related to Galectin-3 and Predicts Outcome in Heart Failure.Biomolecules2023https://conductscience.org/library/papers/36979345PubMed
1231542534Myocardial Tissue Characterization and Fibrosis by Imaging.JACC Cardiovasc Imaging2020https://conductscience.org/library/papers/31542534PubMed
1336221014Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy.Heart Fail Rev2023https://conductscience.org/library/papers/36221014PubMed
1431158407Cardiac fibrosis - A short review of causes and therapeutic strategies.Adv Drug Deliv Rev2019https://conductscience.org/library/papers/31158407PubMed
1537504569Bioactive Compounds and Cardiac Fibrosis: Current Insight and Future Prospect.J Cardiovasc Dev Dis2023https://conductscience.org/library/papers/37504569PubMed
1627226899Antifibrotic therapies to control cardiac fibrosis.Biomater Res2016https://conductscience.org/library/papers/27226899PubMed
1729293097Resolution of organ fibrosis.J Clin Invest2018https://conductscience.org/library/papers/29293097PubMed
1829155002PDGF in organ fibrosis.Mol Aspects Med2018https://conductscience.org/library/papers/29155002PubMed
1930540232Mechanisms for the Resolution of Organ Fibrosis.Physiology (Bethesda)2019https://conductscience.org/library/papers/30540232PubMed
2036140279Novel Therapies for the Treatment of Cardiac Fibrosis Following Myocardial Infarction.Biomedicines2022https://conductscience.org/library/papers/36140279PubMed

See all 202 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
TGFB17040PubTator's text mininghttps://conductscience.org/library/genes/7040

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40908522

GET https://conductscience.org/api/papers/v1/40908522/references?page=2